BW5-13156-49321
2 vaccinations
5 coded responses
12 check-ins
5 free-text entries
0 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 836 / ID
- Registered
- 2021-01-20
- Relationship
- Self
- Race
- N/A
- Ethnicity
- N/A
Timeline
-
2020-12-30
Dose 1 — Pfizer-BioNTech
-
2021-01-20
Registered in v-safe
-
2021-01-20
Dose 2 — Pfizer-BioNTech
-
2021-01-21
Survey response — days 1–6 daily, dose 2MedDRA: Autoimmune disorder, Inflammation — Feeling: Fair · Site: Pain · Headache, Joint pains, Muscle or body aches, Fatigue or tirednessFree text: Systemic flare of inflammation including soreness of prior injuries, surgical sites, and autoimmune disorders.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-01-24
Survey response — days 1–6 daily, dose 2MedDRA: Autoimmune disorder, Inflammation, Pre-existing disease — Feeling: Fair · Joint pains, Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesFree text: Systematic inflammation. Aggravated autoimmune diseases.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-01-25
Survey response — days 1–6 daily, dose 2MedDRA: Condition aggravated, Inflammation, Pre-existing disease — Feeling: Fair · Joint pains, Muscle or body aches, Fatigue or tirednessFree text: Systematic inflammation and aggravation of autoimmune disorders.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-01-26
Survey response — days 1–6 daily, dose 2MedDRA: Condition aggravated, Inflammation, Pre-existing disease — Feeling: Fair · Joint pains, Muscle or body aches, Fatigue or tiredness, Abdominal pain, Rash, not including the immediate area around the injection site · Be unable to do your normal daily activitiesFree text: Systematic inflammation and aggravated autoimmune disorders.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-02-03
- 2021-02-10
- 2021-02-17
- 2021-02-24
- 2021-03-03
- 2021-04-22
- 2021-07-21
-
2022-01-20
Survey response — 12 months, dose 2MedDRA: Arthritis, Eczema, Muscle tightness, Myalgia — Feeling: Fair · Be unable to do your normal daily activitiesFree text: Since Pfizer booster in November 2021: Muscle pain, muscle tension, ongoing systemic inflammation- arthritis, eczema (severity 4/10)MedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-30 | Pfizer-BioNTech | |
| 2 | 2021-01-20 | Pfizer-BioNTech |
Free text
Release 2 — days 1–6 daily, dose 2
Systemic reaction (other): Systemic flare of inflammation including soreness of prior injuries, surgical sites, and autoimmune disorders.
Systemic reaction (other): Systematic inflammation. Aggravated autoimmune diseases.
Systemic reaction (other): Systematic inflammation and aggravation of autoimmune disorders.
Systemic reaction (other): Systematic inflammation and aggravated autoimmune disorders.
Release 10 — 12 months, dose 2
Symptoms: Since Pfizer booster in November 2021: Muscle pain, muscle tension, ongoing systemic inflammation- arthritis, eczema (severity 4/10)
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Arthritis | · | · | ✓ |
| SD | Eczema | · | · | ✓ |
| SD | Muscle tightness | · | · | ✓ |
| SD | Myalgia | · | · | ✓ |
| SRO | Autoimmune disorder | ✓ | ✓ | ✓ |
| SRO | Condition aggravated | ✓ | ✓ | ✓ |
| SRO | Inflammation | ✓ | ✓ | ✓ |
| SRO | Pre-existing disease | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release